Rare case of coexisting ovarian Brenner tumour and ovarian stromal hyperplasia presenting with persistent endometrial hyperplasia following treatment with levonorgestrel-intrauterine system

Endometrial hyperplasia (EH) is a precursor of endometrial cancer. It arises in an environment of unopposed oestrogen. Treatment is based on a combination of weight management, diet and exercise, and the use of progestogens either via a levonogestrel-intrauterine system (LNG-IUS) or orally. The LNG-...

Full description

Saved in:
Bibliographic Details
Published in:BMJ case reports 2022-12, Vol.15 (12), p.e252391
Main Authors: Mok, Zhun Wei, Chin, Janice Pui See
Format: Article
Language:English
Subjects:
Androgens
Biopsy
Body mass index
Brenner Tumor
Case reports
Cervix
Diabetes
Endometrial cancer
Endometrial Hyperplasia - chemically induced
Endometrial Hyperplasia - complications
Endometrial Hyperplasia - pathology
Endometrium
Female
Gynecological cancer
Histology
Humans
Hyperplasia
Hyperplasia - chemically induced
Hysterectomy
Intrauterine Devices, Medicated - adverse effects
Levonorgestrel - adverse effects
Obesity
Oophorectomy
Ovarian Neoplasms - complications
Ovaries
Patients
Polycystic ovary syndrome
Risk factors
Surgery
Tumors
Ultrasonic imaging
Uterus
Weight control
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Endometrial hyperplasia (EH) is a precursor of endometrial cancer. It arises in an environment of unopposed oestrogen. Treatment is based on a combination of weight management, diet and exercise, and the use of progestogens either via a levonogestrel-intrauterine system (LNG-IUS) or orally. The LNG-IUS is the first-line recommendation for EH without atypia. Recurrences are rare, and any recurrences despite prolonged treatment and control of risk factors necessitate a thorough consideration of other oestrogenic sources. This case report presents a rare case of a coexisting ovarian Brenner tumour and ovarian stromal hyperplasia in a menopausal patient in her 50s with recurrent EH despite earlier regression. The above histology may have provided the additional oestrogenic influence. This patient subsequently underwent a definitive hysterectomy and bilateral salpingo-oophorectomy (BSO). It is important to maintain a high index of suspicion for potential oestrogenic influences in cases of refractory EH that are not identifiable on imaging. BSO should be considered at the time of hysterectomy in such cases of unidentified oestrogenic foci.
ISSN:1757-790X
1757-790X
DOI:10.1136/bcr-2022-252391